{
    "id": 13153,
    "fullName": "ALK P1139S",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK P1139S lies within the protein kinase domain of the Alk protein (UniProt.org). P1139S has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 25421750), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "P1139S",
    "createDate": "10/21/2015",
    "updateDate": "09/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 102072,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29222552G>A",
        "cDna": "c.3415C>T",
        "protein": "p.P1139S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3446,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK P1139S in the context of NPM1-ALK in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13329,
                "profileName": "NPM1 - ALK ALK P1139S"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3464,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13329,
                "profileName": "NPM1 - ALK ALK P1139S"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3549,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13329,
                "profileName": "NPM1 - ALK ALK P1139S"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3486,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13329,
                "profileName": "NPM1 - ALK ALK P1139S"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3455,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13329,
                "profileName": "NPM1 - ALK ALK P1139S"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13329,
            "profileName": "NPM1 - ALK ALK P1139S",
            "profileTreatmentApproaches": [
                {
                    "id": 16865,
                    "name": "Alectinib",
                    "profileName": "NPM1 - ALK ALK P1139S"
                },
                {
                    "id": 16864,
                    "name": "Crizotinib",
                    "profileName": "NPM1 - ALK ALK P1139S"
                },
                {
                    "id": 16866,
                    "name": "Brigatinib",
                    "profileName": "NPM1 - ALK ALK P1139S"
                },
                {
                    "id": 16863,
                    "name": "ASP3026",
                    "profileName": "NPM1 - ALK ALK P1139S"
                }
            ]
        },
        {
            "id": 13330,
            "profileName": "ALK P1139S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102072,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29222552G>A",
            "cDna": "c.3415C>T",
            "protein": "p.P1139S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}